Emergent BioSolutions’ (EBS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock.

EBS has been the subject of several other research reports. Benchmark upped their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Saturday, December 28th. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Down 2.2 %

EBS stock opened at $9.87 on Friday. The firm’s fifty day moving average is $9.34 and its 200 day moving average is $9.14. The firm has a market cap of $534.80 million, a PE ratio of -2.41 and a beta of 1.60. Emergent BioSolutions has a one year low of $1.42 and a one year high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC raised its position in shares of Emergent BioSolutions by 267.5% in the second quarter. Acadian Asset Management LLC now owns 108,566 shares of the biopharmaceutical company’s stock valued at $739,000 after buying an additional 79,028 shares during the last quarter. American Century Companies Inc. grew its stake in Emergent BioSolutions by 240.9% during the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after acquiring an additional 623,201 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Emergent BioSolutions in the 2nd quarter valued at about $41,000. Federated Hermes Inc. lifted its stake in Emergent BioSolutions by 1,314.0% in the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock worth $1,864,000 after purchasing an additional 253,960 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Emergent BioSolutions during the 2nd quarter worth approximately $93,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.